Pardes Biosciences Ownership
Pardes Biosciences owns a total of 62.01 Million outstanding shares. The majority of Pardes Biosciences outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Pardes Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Pardes Biosciences. Please pay attention to any change in the institutional holdings of Pardes Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Pardes |
Pardes Stock Ownership Analysis
About 13.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.37. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pardes Biosciences recorded a loss per share of 1.28. The entity had not issued any dividends in recent years. Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. The company was incorporated in 2020 and is headquartered in Carlsbad, California. Pardes Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 61 people. To find out more about Pardes Biosciences contact Thomas Wiggans at 415 649 8758 or learn more at https://www.pardesbio.com.Pardes Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pardes Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pardes Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pardes Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Henson Heidi over a year ago Disposition pursuant to a tender of shares in a change of control transaction by Henson Heidi of Pardes Biosciences | ||
Auerbach Mark over a year ago Acquisition by Auerbach Mark of 37500 shares of Pardes Biosciences subject to Rule 16b-3 | ||
Foresite Capital Management V Llc over a year ago Purchase by Foresite Capital Management V Llc of 773952 shares of Pardes Biosciences | ||
Sean Brusky over a year ago Acquisition by Sean Brusky of 156250 shares of Pardes Biosciences subject to Rule 16b-3 |
Pardes Biosciences Outstanding Bonds
Pardes Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pardes Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pardes bonds can be classified according to their maturity, which is the date when Pardes Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Pardes Stock
If you are still planning to invest in Pardes Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pardes Biosciences' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |